We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Drug Discovery

Drug Discovery

Featured Articles

Multichannel pipette dispensing samples into a 96-well plate during high-throughput screening.

How High-Throughput Screening Is Transforming Modern Drug Discovery

This article explores how advances in automation, 3D cell models and AI are transforming high-throughput screening, driving faster and more predictive drug discovery.

Modern data center with illuminated server racks, representing digital science infrastructure.

Will Labs Wake Up to the Environmental Cost of Data Crunching?

The rise of digital science is reshaping lab sustainability. In this article, experts highlight the need for new standards to account for computing’s growing environmental impact.

3D illustration of antibodies, central to immune responses in both cancer and allergy research.

The Surprising Connection Between Cancer and Allergy

IgE, best known for mediating allergic reactions, may also shape cancer outcomes. Learn how this immune molecule could serve as both a biomarker and a basis for next-generation therapies.

Latest Articles

Separating ELA from the Crowd

Select Biosciences, organizers of European Lab Automation (ELA) 2011, announces that the inaugural Advances in Separation Technology (AST) conference will form one of the ten conference streams at ELA.

New Life Science Awards Event Precedes ELA 2011

Select Biosciences and co-organisers, Langton Howarth, announce that the inaugural Life Science Awards will be held on the evening of 29 June at the Radisson Blu Hotel, Hamburg, Germany.

Agendas online

The conference agendas for ADMET Europe, MedChem Europe, Pharma Outsourcing Congress and Flow Chemistry Europe to be held 28-29 March, 2011 in Munich, Germany have now been released.

Cytheris Initiates INSPIRE 3, a Phase II Clinical Trial of CYT107 in Chronically Infected HIV Patients

Phase II clinical program will evaluate the effect of repeated cycles of the company’s investigative immune-modulator in the treatment of Immunological Non-Responders.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter